

## Haematological cancers

**Consultation on draft quality standard – deadline for comments 5pm on 07/02/17 email: [QSconsultations@nice.org.uk](mailto:QSconsultations@nice.org.uk)**

	<p>Please read the checklist for submitting comments at the end of this form. We cannot accept forms that are not filled in correctly.</p> <p>We would like to hear your views on these questions:</p> <ol style="list-style-type: none"><li>1. Does this draft quality standard accurately reflect the key areas for quality improvement? If the systems and structures were available, do you think it would be possible to collect the data for the proposed quality measures? Do you have an example from practice of implementing the NICE guideline(s) that underpins this quality standard? If so, please submit your example to the <a href="#">NICE local practice collection</a> on the NICE website. Examples of using NICE quality standards can also be submitted.</li><li>2. [Insert any specific questions about the quality standard from the Developer, or delete if not needed]</li></ol>
<b>Organisation name – stakeholder or respondent</b> (if you are responding as an individual rather than a registered stakeholder please leave blank):	[British HIV Association]
<b>Disclosure</b> Please disclose any past or current, direct or indirect links to, or funding from, the tobacco industry.	[None]
<b>Name of commentator person completing form:</b>	[Professor Mark Bower]

Consultation on draft quality standard – deadline for comments **5pm** on **07/02/17** email: [QSconsultations@nice.org.uk](mailto:QSconsultations@nice.org.uk)

<b>Supporting the quality standard</b> - Would your organisation like to express an interest in formally supporting this quality standard? <a href="#">More information.</a>		<b>[Answer Yes or No]</b>	
<b>Type</b>		<b>[office use only]</b>	
<b>Comment number</b>	<b>Section</b>	<b>Statement number</b>	<b>Comments</b>
Insert each comment in a new row. Do not paste other tables into this table because your comments could get lost – type directly into this table.			
Example 1	Statement 1 (measure)		This statement may be hard to measure because...
1			BHIVA considers that it is a great shame that again NICE has failed to ensure that all young people and adults with lymphoma have an HIV test before starting anti-cancer treatment, as the anti-cancer treatment will have significant deleterious effects on the health of people with untreated HIV infection and result in higher death rates.
2			
3			
4			
5			
6			

Insert extra rows as needed

**Checklist for submitting comments**

- Use this comment form and submit it as a Word document (not a PDF).
- Complete the disclosure about links with, or funding from, the tobacco industry.
- Include section number of the text each comment is about eg. introduction; quality statement 1; quality statement 2 (measure).
- If commenting on a specific quality statement, please indicate the particular sub-section (for example, statement, measure or audience descriptor).

Please return to: [QSconsultations@nice.org.uk](mailto:QSconsultations@nice.org.uk)

## Haematological cancers

**Consultation on draft quality standard – deadline for comments 5pm on 07/02/17 email: [QSconsultations@nice.org.uk](mailto:QSconsultations@nice.org.uk)**

- Combine all comments from your organisation into 1 response. We cannot accept more than 1 response from each organisation.
- Do not paste other tables into this table – type directly into the table.
- Underline and highlight any confidential information or other material that you do not wish to be made public.
- Do not include medical information about yourself or another person from which you or the person could be identified.
- Spell out any abbreviations you use
- For copyright reasons, comment forms do not include attachments such as research articles, letters or leaflets (for copyright reasons). We return comment forms that have attachments without reading them. The stakeholder may resubmit the form without attachments, but it must be received by the deadline.

You can see any guidance and quality standards that we have produced on topics related to this quality standard by checking [NICE Pathways](#).

**Note:** We reserve the right to summarise and edit comments received during consultations, or not to publish them at all, if we consider the comments are too long, or publication would be unlawful or otherwise inappropriate.

Comments received from registered stakeholders and respondents during our consultations are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the comments we received, and are not endorsed by NICE, its officers or advisory Committees.